Please login to the form below
Intercept
This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.
Better together when buying medicines? Taking stock of the BeNeLuxA initiative
was subsequently updated) for Vertex’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor), Intercept’s Ocaliva (obeticholic acid) for primary biliary cholangitis and for Biogen’s Spinraza (nusinersen) for spinal muscular atrophy
Latest news
-
Roche enters NASH race with deal to buy Jecure
Among these, Intercept’s Ocaliva (obeticholic acid) is already approved to treat rare liver disease primary biliary cirrhosis, and is in phase 3 for NASH patients with cirrhosis, while Gilead Sciences
-
Gilead NASH drug clears mid-stage trial, but rivals are looming
Positive results to challenge Intercept in emerging disease area. Gilead has new data backing up its liver disease candidate GS-9674 in non-alcoholic steatohepatitis (NASH), tipped as one of the ... The new data shows Gilead’s drug is working as
-
Novartis and Pfizer to collaborate on NASH combinations
needs.”. Other companies such as Intercept, Allergan and Gilead have FXR agonists in their pipelines, but Gilead suffered a disappointment when its candidate failed to show efficacy a recent phase 2 ... Intercept’s Ocaliva (obeticholic acid, an FXR
-
Orphan drugs dominate UK Prix Galien shortlist, medtech debuts
Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).
-
Intercept hit hard as FDA issues Ocaliva safety notice
Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in December. ... Intercept can muster approvals in additional indications such as non-alcoholic steatohepatitis (NASH) for which it is in
More from news
Approximately 6 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Simon Doyle joins STEM
Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
-
Glenn Sblendorio to retire as president of The Medicines Company
He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Blog: 5 ingredients: Multichannel marketing, simplified
Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
-
Market Insights Can Deliver a Better Patient Experience
Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Account Manager
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Global Business Development Director – Health Education
-
excellent commission
-
Account Director, Medical Education
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
-
Account Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
